Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity.
In attempting to account for the ability of most solid tumors to restrict the absorption of WR-2721, aminopropyl-aminoethylphosphorothioate, we examined a number of drug characteristics which might allow for this restriction, and observed that drug hydrophilicity was a major contributing factor. When the highly hydrophilic WR-2721 was dephosphorylated, the drug became less hydrophilic and could readily cross tumor cell membranes. In addition, conventional radioprotectants, such as cysteine and mercaptoethylamine, were shown to be less hydrophilic than WR-2721 and also to cross tumor membranes readily. Therefore, drug hydrophilicity would appear to be the factor underlying the ability of WR-2721 to selectively protect normal tissues while most other protectors alter the radiation resistance of normal and tumor tissue alike. A red blood cell model for studying this problem in greater detail is described.
D000042:Absorption; D004999:Amifostine / Q000378:metabolism*; D000818:Animals; D002463:Cell Membrane Permeability; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D009374:Neoplasms, Experimental / Q000378:metabolism*; D009447:Neuroblastoma / Q000378:metabolism; D009946:Organothiophosphorus Compounds / Q000378:metabolism*; D011073:Polyamines / Q000378:metabolism; D051381:Rats; D012995:Solubility
D009946:Organothiophosphorus Compounds; D011073:Polyamines; D004999:Amifostine